Related Experiment Video

Updated: Nov 1, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

["Treatment of bladder cancer with immune checkpoints inhibitors"]

Élisabeth Grobet-Jeandin1, Ugo Pinar2, Yohann Loriot3

  • 1Département d'urologie, Hôpitaux universitaires de Genève, Genève, Suisse - Sorbonne Université, GRC n° 5, PREDICTIVE ONCO-UROLOGY, AP-HP, groupe hospitalier La Pitié-Salpêtrière, service d'urologie, Paris, France.

La Revue Du Praticien
|June 23, 2021
PubMed

Insights

Immune checkpoint inhibitors offer significant improvements for bladder cancer treatment. These therapies enhance survival in metastatic cases and show promise for muscle-invasive and non-muscle-invasive bladder cancer management.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Bladder cancer presents significant treatment challenges across various stages.
  • Current treatments like chemotherapy and Bacillus Calmette-Guérin (BCG) have limitations.

Purpose of the Study:

  • To evaluate the role and efficacy of immune checkpoint inhibitors in managing different forms of bladder cancer.
  • To explore the potential of immune checkpoint inhibitors as alternatives or adjuncts to existing therapies.

Main Methods:

  • Review of clinical data and trial outcomes for immune checkpoint inhibitors in bladder cancer.
  • Analysis of survival data and recurrence rates in patients treated with these novel agents.

Main Results:

  • Immune checkpoint inhibitors demonstrate improved overall survival in metastatic bladder cancer, recommended as second-line therapy.
  • These inhibitors show potential to replace chemotherapy for muscle-invasive bladder cancer.
  • A reduced risk of recurrence is observed after BCG treatment failure in non-muscle-invasive bladder cancer.

Conclusions:

  • Immune checkpoint inhibitors represent a significant advancement in bladder cancer management.
  • Ongoing trials are crucial to further establish the value of these agents across all bladder cancer subtypes.
Keywords:
ImmunotherapyUrinary Bladder Neoplasms

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

744

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
790
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
590
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K